Search - tctmd.com

Displaying 421 - 440 of 946

Sort: Relevancy | Date

News Conference News EHRA 2019

For Acute A-fib, Wait-and-See Approach May Spare Many Patients From Cardioversion

Todd Neale

March 18, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Conference News CRT 2019

BASILICA Leaflet Laceration Before TAVR Helps Prevent Coronary Obstruction

Yael L. Maxwell

March 04, 2019

News Conference News CRT 2019

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

Yael L. Maxwell

March 03, 2019

News Conference News CRT 2019

New ALERTS Data Support Use of Implantable Cardiac Monitor in High-Risk ACS Patients—With Caveats

Yael L. Maxwell

March 03, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Conference News ISC 2019

Off-Label Underdosing of DOACs Tied to Worse Outcomes in A-fib Patients

Todd Neale

February 07, 2019

News Conference News ISET 2019

Surmounting Minor Stroke: New Devices, TCAR Aim to Cut Risk of Carotid Artery Stenting

Caitlin E. Cox

January 31, 2019

Presentation ISET 2019

Drug-Coated Therapy for ISR: Review of Options and Data

Presenter: Brian DeRubertis

January 30, 2019

News Conference News STS 2019

TAVR-Related Complications, High Resource Use Decreasing at a Surgeon-Led Program

Yael L. Maxwell

January 30, 2019

News Daily News

Aspiration Thrombectomy on the Decline as New Study Affirms No Benefit in STEMI

Michael O'Riordan

January 15, 2019

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Vote

News Daily News

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review

Caitlin E. Cox

January 11, 2019

News Daily News

Cancer Patients Should Not Be Automatically Ruled Out for TAVR: Analysis

L.A. McKeown

January 10, 2019

News Featured Fellow

Marinos Charalambous, MD

Yael L. Maxwell

January 09, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

News Daily News

Data Hint at Unintended Consequences of Hospital Readmissions Reduction Program

L.A. McKeown

December 21, 2018

News Daily News

Hospitals With Higher SAVR Mortality Likely to Have Higher TAVR Mortality, Too

L.A. McKeown

December 12, 2018

News Daily News

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Michael O'Riordan

October 25, 2018

News Daily News

Isolated SAVR Volumes Slide as TAVR Numbers Mount in the US

Yael L. Maxwell

October 19, 2018

Advertisement

For Acute A-fib, Wait-and-See Approach May Spare Many Patients From Cardioversion

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

BASILICA Leaflet Laceration Before TAVR Helps Prevent Coronary Obstruction

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

New ALERTS Data Support Use of Implantable Cardiac Monitor in High-Risk ACS Patients—With Caveats

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

Off-Label Underdosing of DOACs Tied to Worse Outcomes in A-fib Patients

Surmounting Minor Stroke: New Devices, TCAR Aim to Cut Risk of Carotid Artery Stenting

Drug-Coated Therapy for ISR: Review of Options and Data

TAVR-Related Complications, High Resource Use Decreasing at a Surgeon-Led Program

Aspiration Thrombectomy on the Decline as New Study Affirms No Benefit in STEMI

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review

Cancer Patients Should Not Be Automatically Ruled Out for TAVR: Analysis

Marinos Charalambous, MD

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Data Hint at Unintended Consequences of Hospital Readmissions Reduction Program

Hospitals With Higher SAVR Mortality Likely to Have Higher TAVR Mortality, Too

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Isolated SAVR Volumes Slide as TAVR Numbers Mount in the US

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content